TD Cowen Upgrades Bruker (NASDAQ:BRKR) to “Hold”

Bruker (NASDAQ:BRKR) was upgraded by TD Cowen to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other equities research analysts have also weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. The Goldman Sachs Group decreased their price target on shares of Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a research note on Friday, February 13th. Jefferies Financial Group set a $50.00 price objective on Bruker in a research report on Thursday, February 12th. UBS Group restated a “neutral” rating and issued a $49.00 price target on shares of Bruker in a research report on Friday, February 13th. Finally, Barclays dropped their price target on Bruker from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $49.38.

Bruker Stock Performance

BRKR stock opened at $39.90 on Monday. The stock’s 50 day simple moving average is $37.58 and its 200 day simple moving average is $41.71. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. Bruker has a 12-month low of $28.53 and a 12-month high of $56.22. The stock has a market capitalization of $6.07 billion, a PE ratio of -266.00, a price-to-earnings-growth ratio of 2.34 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). The business had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.During the same quarter in the previous year, the business posted $0.76 earnings per share. Bruker’s quarterly revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts forecast that Bruker will post 2.69 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Mark Munch sold 2,000 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $35.44, for a total value of $70,880.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $4,552,019.92. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently made changes to their positions in the company. Orbis Allan Gray Ltd increased its stake in shares of Bruker by 5.4% during the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock valued at $702,256,000 after buying an additional 761,258 shares during the period. State Street Corp lifted its stake in Bruker by 2.5% in the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock worth $180,700,000 after acquiring an additional 91,706 shares during the period. AQR Capital Management LLC grew its holdings in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Sculptor Capital LP grew its holdings in Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after acquiring an additional 476,363 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Bruker by 2,963.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after purchasing an additional 2,289,269 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.